Stock Market Reviews

MLYS (Mineralys Therapeutics, Inc.) News

Get the latest news, insights, and market updates on MLYS (Mineralys Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy?
  Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Sep 29, 2025 - $MLYS
• These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
  Here's what needs to happen for these high flyers to continue soaring.
  Sep 21, 2025 - $MLYS
• Did New Phase 3 Results and FDA Milestones Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?
  Mineralys Therapeutics recently announced new subgroup results from its Phase 3 Launch-HTN trial of lorundrostat, presented at the American Heart Association Hypertension Scientific Sessions in early September 2025, highlighting consistent and meaningful blood pressure reductions in high-risk patient groups with favorable safety outcomes. Significantly, Mineralys also revealed plans for a pre-NDA meeting with the FDA in late 2025 and an NDA filing as early as the first quarter of 2026,...
  Sep 17, 2025 - $MLYS
• What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?
  Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Sep 9, 2025 - $MLYS
• These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
  Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.
  Sep 7, 2025 - $MLYS
• Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
  ~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and participants with comorbid obesity – face heightened risk of poor cardiovascular outcomes and represent high unmet need~ ~Lorundrostat demonstrated significant and clinically meaningful blood pressure reductions across all participant subgroups, with a
  Sep 5, 2025 - $MLYS
• Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
  RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of its previously announced underwritten public offering of 11,274,509 shares of its common stock, which includes the exercise in fu
  Sep 4, 2025 - $MLYS
• Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Key Labor Market Data
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad
  Sep 3, 2025 - $MLYS
• Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak
  We recently published 10 Power Stocks Crushing Wall Street — 7 at All-Time Highs. Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the best performers on Tuesday. Mineralys surged to a new all-time high on Tuesday, as investors gobbled up shares after one of its counterparts posted positive trial results for its aldosterone synthase inhibitor (ASI), […]
  Sep 3, 2025 - $MLYS
• Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
  RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an upsized underwritten public offering of 9,803,921 shares of its common stock at a public offering price of $25.50 per share. T
  Sep 3, 2025 - $MLYS